Literature DB >> 8369164

Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization.

P J Klasse1, J A McKeating.   

Abstract

The selection of HIV-1 resistance to neutralization by both monovalent and bivalent forms of soluble CD4 was demonstrated under various conditions. Phenotypic traits of the neutralization-resistant variants were systematically explored in order to gain insight into which aspects of the interactions with CD4 are most expendable to HIV-1 replication. The size of the nonneutralized fraction after treatment of preparations of the HIV-1 isolate IIIB and a molecular clone derived from it (HX10), with either monovalent soluble CD4 (sCD4) or bivalent CD4-Ig, was determined. These fractions were greater for the polyclonal IIIB than for the viral clone, and greater after treatment with sCD4 than with CD4-Ig. The virus in the nonneutralized fractions exhibited 2- to 20-fold lower sensitivity to the neutralizing agents than did unselected virus. In addition, clonal HIV-1 (HX10) was cultured in the presence of sCD4 or CD4-Ig for 12 weeks, so as to allow for accumulation of mutations that would confer stronger resistance to the selecting agent. Variants were obtained with up to 100-fold increased resistance to sCD4 or CD4-Ig. Detergent-solubilized gp120 from sCD4- and CD4-Ig-selected virus showed decreases in affinity for sCD4 and CD4-Ig. The monoclonal antibodies 6H10, to the gp120-binding site in domain 1 of CD4, and 5A8, to domain 2 of CD4, inhibited the induction by the viral escape variants of syncytium formation of C8166 cells. In general, the concentration of antibody 6H10 that inhibited the escape variants was lower than the concentration that inhibited the wild type, whereas there was no significant difference for the domain 2 antibody 5A8. We interpret this as a weaker attachment of the escape variants than of the wild-type virus to cellular CD4, but as an intact dependence of the variants on CD4 interactions for gaining entry into cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8369164     DOI: 10.1089/aid.1993.9.595

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  10 in total

1.  Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.

Authors:  N Genois; B Barbeau; M Olivier; M J Tremblay
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes.

Authors:  L J Cooper; M Kalos; D A Lewinsohn; S R Riddell; P D Greenberg
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Identification of key residues in subgroup A avian leukosis virus envelope determining receptor binding affinity and infectivity of cells expressing chicken or quail Tva receptor.

Authors:  S L Holmen; D C Melder; M J Federspiel
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

4.  Soluble forms of the subgroup A avian leukosis virus [ALV(A)] receptor Tva significantly inhibit ALV(A) infection in vitro and in vivo.

Authors:  S L Holmen; D W Salter; W S Payne; J B Dodgson; S H Hughes; M J Federspiel
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 5.  Molecular determinants of the ratio of inert to infectious virus particles.

Authors:  P J Klasse
Journal:  Prog Mol Biol Transl Sci       Date:  2014-12-01       Impact factor: 3.622

6.  Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.

Authors:  F Verrier; A Nádas; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

Authors:  P J Klasse; J P Moore
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.

Authors:  Per Johan Klasse
Journal:  Virology       Date:  2007-09-07       Impact factor: 3.616

9.  Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules.

Authors:  M C Gauduin; G P Allaway; P J Maddon; C F Barbas; D R Burton; R A Koup
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.

Authors:  David Beauparlant; Peter Rusert; Carsten Magnus; Claus Kadelka; Jacqueline Weber; Therese Uhr; Osvaldo Zagordi; Corinna Oberle; Maria J Duenas-Decamp; Paul R Clapham; Karin J Metzner; Huldrych F Günthard; Alexandra Trkola
Journal:  PLoS Pathog       Date:  2017-03-06       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.